Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. IBM
10. KNX

Go back to Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
ALKERMES (NASDAQ: ALKS) Delayed: 52.97 +0.39 (0.74%)
Previous Close $52.58    52 Week High $80.71 
Open $52.13    52 Week Low $27.14 
Day High $53.54    P/E 407.46 
Day Low $51.69    EPS $0.13 
Volume 1,488,265